- Wedbush is skeptical about Xylem's (XYL +2.1%) executive shakeup.
- "Today's announcement that President and CEO Gretchen McClain has stepped down suggests the road ahead may be more challenging than we had anticipated," analyst David Rose says.
- Rose calls the shares' performance since the ITT spinoff "lackluster" and notes that given the company's recent earnings report (Q2 adjusted EPS -26% Y/Y, negative organic revenue growth, disappointing guidance), "the case had not been made that a turnaround [is] imminent."
- Neutral rating maintained, price target $27.
Wedbush cautious on Xylem after CEO resignation
From other sites
at CNBC.com (Jul 28, 2014)
at CNBC.com (Sep 26, 2013)
at CNBC.com (Aug 21, 2013)
at CNBC.com (Dec 7, 2012)
at CNBC.com (Apr 3, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs